SAN2668
A potential first-in-class therapy for severe pediatric epilepsies
SAN2668 is Saniona’s lead clinical candidate for the treatment of severe pediatric epilepsies, including Developmental Epileptic Encephalopathies (DEEs). These syndromes are often drug-resistant, lack approved therapies, and have lifelong consequences for patients and families.
SAN2668
Designed with selective pharmacology targeting all GABAA receptor subtypes involved in seizure control, SAN2668 offers a precision approach to seizure prevention while minimizing liability for tolerance development, sedation, cognitive impairment, and motor side effects. Its profile supports the potential for best-in-class efficacy for children with difficult-to-treat epilepsy syndromes.
SAN2668 is progressing toward Phase 1 clinical trials in 2026. In addition to safety and tolerability the planned clinical assessments include pharmacodynamic and target engagement studies to provide early validation of its mechanism of action and its ability to achieve therapeutic receptor occupancy levels associated with robust anti-seizure efficacy. These data will inform rational dose selection for Phase 2, supporting an optimal balance between efficacy and tolerability in pediatric populations.
The program reflects Saniona’s commitment to advancing transformative ion channel modulators for rare and severe CNS disorders.
SAN2668 STATUS
SAN2668 is progressing toward Phase 1 clinical trials in 2026